NanoString nCounter Vantage Assays
Nanostring Technologies has launched its nCounter Vantage assay portfolio to power 3D biology experiments in cancer research. The portfolio includes two new RNA panels for the detection of fusion genes in lung cancer and leukemia samples, two new protein panels covering solid tumor biology and immune-cell signaling, and one new DNA panel for the detection of single nucleotide variations. The assays allow for multiplexed, digital analysis of DNA, RNA and protein simultaneously in a single experiment, the company said.
The new assays will be featured at the American Association for Cancer Research's annual meeting taking place in New Orleans, April 17-20.